These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia. Nassereddine S; Lap CJ; Haroun F; Tabbara I Ann Hematol; 2017 Dec; 96(12):1983-1991. PubMed ID: 29090344 [TBL] [Abstract][Full Text] [Related]
4. IDH mutations in cancer and progress toward development of targeted therapeutics. Dang L; Yen K; Attar EC Ann Oncol; 2016 Apr; 27(4):599-608. PubMed ID: 27005468 [TBL] [Abstract][Full Text] [Related]
6. Molecular Targeting of the Isocitrate Dehydrogenase Pathway and the Implications for Cancer Therapy. Ivanov S; Nano O; Hana C; Bonano-Rios A; Hussein A Int J Mol Sci; 2024 Jul; 25(13):. PubMed ID: 39000443 [TBL] [Abstract][Full Text] [Related]
7. The role of IDH mutations in acute myeloid leukemia. Montalban-Bravo G; DiNardo CD Future Oncol; 2018 Apr; 14(10):979-993. PubMed ID: 29543066 [TBL] [Abstract][Full Text] [Related]
8. Isocitrate Dehydrogenase Mutations in Cancer: Mechanisms of Transformation and Metabolic Liability. Gunn K; Losman JA Cold Spring Harb Perspect Med; 2024 May; 14(5):. PubMed ID: 38191174 [TBL] [Abstract][Full Text] [Related]
9. Oncogenic Activities of IDH1/2 Mutations: From Epigenetics to Cellular Signaling. M Gagné L; Boulay K; Topisirovic I; Huot MÉ; Mallette FA Trends Cell Biol; 2017 Oct; 27(10):738-752. PubMed ID: 28711227 [TBL] [Abstract][Full Text] [Related]
10. Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer. Sharma H Curr Top Med Chem; 2018; 18(6):505-524. PubMed ID: 29773061 [TBL] [Abstract][Full Text] [Related]
11. Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer. Clark O; Yen K; Mellinghoff IK Clin Cancer Res; 2016 Apr; 22(8):1837-42. PubMed ID: 26819452 [TBL] [Abstract][Full Text] [Related]
12. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients. Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365 [TBL] [Abstract][Full Text] [Related]
13. Reductive TCA cycle catalyzed by wild-type IDH2 promotes acute myeloid leukemia and is a metabolic vulnerability for potential targeted therapy. Zeng P; Lu W; Tian J; Qiao S; Li J; Glorieux C; Wen S; Zhang H; Li Y; Huang P J Hematol Oncol; 2022 Mar; 15(1):30. PubMed ID: 35313945 [TBL] [Abstract][Full Text] [Related]
14. Mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 in tumors. Schaap FG; French PJ; Bovée JV Adv Anat Pathol; 2013 Jan; 20(1):32-8. PubMed ID: 23232569 [TBL] [Abstract][Full Text] [Related]
15. Isocitrate dehydrogenase mutations in myeloid malignancies. Medeiros BC; Fathi AT; DiNardo CD; Pollyea DA; Chan SM; Swords R Leukemia; 2017 Feb; 31(2):272-281. PubMed ID: 27721426 [TBL] [Abstract][Full Text] [Related]
16. Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis. Ohba S; Hirose Y Neurol Med Chir (Tokyo); 2016; 56(4):170-9. PubMed ID: 26960449 [TBL] [Abstract][Full Text] [Related]
17. Isocitrate dehydrogenase gene mutations and 2-hydroxyglutarate accumulation in esophageal squamous cell carcinoma. Miyake K; Baba Y; Ishimoto T; Hiyoshi Y; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Ogata Y; Nagayama M; Silsirivanit A; Kobayashi D; Araki N; Baba H Med Oncol; 2018 Nov; 36(1):11. PubMed ID: 30506321 [TBL] [Abstract][Full Text] [Related]
18. Emerging drug profile: Krebs cycle and cancer: IDH mutations and therapeutic implications. Lee S; Urman A; Desai P Leuk Lymphoma; 2019 Nov; 60(11):2635-2645. PubMed ID: 30958073 [TBL] [Abstract][Full Text] [Related]